73504-43-5

Upstream product

• 27513-44-6 N-tert-butoxycarbonyl-O-benzyl-(S)-tyrosine methyl ester 
• 100-44-7 benzyl chloride 
• 4326-36-7 (S)-N-(tert-butoxycarbonyl)tyrosine methyl ester 
• 2130-96-3 O-benzyl-N-tert-butoxycarbonyl-L-tyrosine 
• 35229-21-1 Boc-Tyr(Bzl)-NH₂ 

Downstream Products

• 155163-73-8 3-(4-benzyloxyphenyl)propane-1,2-diamine 
• 886758-82-3 {(S)-1-[(S)-2-(4-Benzyloxy-phenyl)-1-carbamoyl-ethylcarbamoyl]-3-methyl-butyl}-carbamic acid benzyl ester 
• 869110-66-7 Hexadecanoic acid (R)-2-(benzyloxy-{4-[(S)-2,3-bis-(bis-tert-butoxycarbonylmethyl-amino)-propyl]-phenoxy}-phosphoryloxy)-1-hexadecanoyloxymethyl-ethyl ester 
• 869110-65-6 Hexadecanoic acid (R)-2-(benzyloxy-{4-[(S)-2,3-bis-(bis-tert-butoxycarbonylmethyl-amino)-propyl]-phenoxy}-phosphanyloxy)-1-hexadecanoyloxymethyl-ethyl ester 
• 869110-67-8 Hexadecanoic acid (R)-2-({4-[(S)-2,3-bis-(bis-tert-butoxycarbonylmethyl-amino)-propyl]-phenoxy}-hydroxy-phosphoryloxy)-1-hexadecanoyloxymethyl-ethyl ester 
• 869110-68-9 Hexadecanoic acid (R)-2-({4-[(S)-2,3-bis-(bis-carboxymethyl-amino)-propyl]-phenoxy}-hydroxy-phosphoryloxy)-1-hexadecanoyloxymethyl-ethyl ester 
• 869110-69-0 {[1-(4-benzyloxy-benzyl)-2-(bis-tert-butoxycarbonylmethyl-amino)-ethyl]-tert-butoxycarbonylmethyl-amino}-acetic acid tert-butyl ester 
• 869110-64-5 {[2-(bis-tert-butoxycarbonylmethyl-amino)-1-(4-hydroxy-benzyl)-ethyl]-tert-butoxycarbonylmethyl-amino}-acetic acid tert-butyl ester 

Relevant academic research and scientific papers

Mn(II) Complex of Lipophilic Group-Modified Ethylenediaminetetraacetic Acid (EDTA) as a New Hepatobiliary MRI Contrast Agent

Liver-specific contrast agents (CAs) can improve the Magnetic resonance imaging (MRI) detection of focal and diffuse liver lesions by increasing the lesion-to-liver contrast. A novel Mn(II) complex, Mn-BnO-TyrEDTA, with a lipophilic group-modified ethylenediaminetetraacetic acid (EDTA) structure as a ligand to regulate its behavior in vivo, is superior to Gd-EOB-DTPA in terms of a liver-specific MRI contrast agent. An MRI study on mice demonstrated that Mn-BnO-TyrEDTA can be rapidly taken up by hepatocytes with a combination of hepatobiliary and renal clearance pathways. Bromosulfophthalein (BSP) inhibition imaging, biodistribution, and cellular uptake studies confirmed that the mechanism of hepatic targeting of Mn-BnO-TyrEDTA is the hepatic uptake of the amphiphilic anion contrast agent mediated by organic anion transporting polypeptides (OATPs) expressed by functional hepatocytes.

Dipeptide nitrile inhibitors of cathepsin K

A series of dipeptidyl nitriles as inhibitors of cathepsin K have been explored starting from lead structure 1 (Cbz-Leu-NH-CH2-CN, IC 50 = 39 nM). Attachment of non-natural amino acid side chains in P1 and modification of the P3 subu